Login to Your Account



Akashi suspends DMD trial as patient's health deteriorates

By Michael Fitzhugh
Staff Writer

Tuesday, January 26, 2016

Dosing and new patient enrollment in all cohorts of Akashi Therapeutics Inc.'s phase Ib/IIa study of the FDA fast-tracked experimental Duchenne muscular dystrophy (DMD) medicine HT-100 (halofuginone) are being suspended after one of the patients receiving the highest study dose began experiencing serious, life-threatening health issues.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription